Robin Swartz compensation by year
Voyager Therapeutics Summary Compensation Table · all 2 fiscal years held| Component | FY2023 | FY2025 |
|---|---|---|
| Salary | $449,400 | $520,190 |
| Bonus | $0 | $0 |
| Stock awards | $297,200 | $300,675 |
| Option awards | $422,088 | $414,675 |
| Non-equity incentive | $199,534 | $205,475 |
| Pension and deferred compensation | $0 | $0 |
| All other | $13,050 | $13,285 |
| Total | $1,381,272 | $1,454,300 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Voyager Therapeutics, Inc. DEF 14A filed April 28, 2026, accession 0001104659-26-050297, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Voyager Therapeutics, Inc. filed document, accession 0001104659-26-050297. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 78,000 | $306,540 | — |
| RSU | 71,250 | $280,013 | — |
| RSU | 33,334 | $131,003 | — |
| RSU | 13,333 | $52,399 | — |
| Option | 56,000 | — | $7.60 |
| Option | 2,500 | — | $2.85 |
| Option | 5,200 | — | $3.32 |
| Option | 23,334 | — | $7.43 |
| Option | 114,000 | — | $4.22 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Voyager Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
2 Form 4 lines since the FY2025 proxy (filed April 28, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-11-01 | Grant or award derivative | — | 318,500 | $0.00 | 318,500 |
| 2026-11-01 | Grant or award | — | 68,250 | $0.00 | 267,988 |
The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Voyager Therapeutics discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | $541,518 | $769,555 | — | — |
| Change in control and resignation for good reason | $541,518 | $769,555 | — | — |
| Resignation for good reason, no change in control | $541,518 | $0 | — | — |
| Involuntary termination without cause | $541,518 | $0 | — | — |
Per the Potential Payments Upon Termination or Change in Control table in Voyager Therapeutics, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Voyager Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Alfred Sandrock | Chief Executive Officer, President, and Director | $2,508,370 |
| Jacquelyn Fahey Sandell | Former Chief Legal Officer | $1,474,986 |
| Robin Swartz · this page | Chief Business Officer & Chief Operating Officer | $1,454,300 |
| Toby Ferguson | Former Chief Medical Officer | $1,364,420 |
Robin Swartz's compensation dossier, Voyager Therapeutics
You have read Robin Swartz's totals and holdings. The dossier adds each equity grant Voyager Therapeutics disclosed for Robin Swartz and Voyager Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Voyager Therapeutics compensation record
free company briefThis page is one person within Voyager Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Voyager Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Voyager Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Voyager Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order VYGR
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.